SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUniphar Regulatory News (UPR)

Share Price Information for Uniphar (UPR)

Share Price is delayed by 15 minutes
Get Live Data
416.00    2.00 (0.48%)
Bid:
414.00
Ask:
418.00
Spread: 4.00 (0.966%)
Market Cap: £1.08b
UPR Live PriceLast checked at - London Stock Exchange

Intraday Uniphar Share Chart

AGM Update

19 May 2020 07:00

RNS Number : 2730N
Uniphar PLC
19 May 2020
 

 

 

 

AGM Update

 

 

Dublin, London | 19 May 2020

 

As set out in the Notice of AGM published on 24 April 2020, the annual general meeting of Uniphar plc (the "Company") is scheduled to take place at 11am on 26 May 2020 at Uniphar's registered office, 4045 Kingswood Road, Citywest Business Park, Dublin 24, D24 V06K (the "AGM").

Following the Irish Government's latest announcement on 15 May 2020 on Covid-19 restrictions, significant restrictions on internal gatherings of people not from the same household will remain in place on 26 May 2020. Accordingly, shareholders are requested not to attend the AGM in person and instead to submit a proxy form to ensure they can vote and be represented at the AGM without attending in person.

The Company regrets the need to take this step but is doing so to safeguard the health of its shareholders and employees and to ensure all government guidelines are followed, ensuring the AGM is as safe and efficient as possible.

 

Uniphar encourages all shareholders to avail of the other methods outlined below to ensure effective shareholder participation in the AGM.

 

Voting

 

All resolutions at the AGM will be put to a poll (which incorporates proxy votes received within the prescribed timelines prior to the meeting) and the Company will publish the results of the poll on its website following the AGM. Proxy voting can be carried out in advance of the AGM in one of the following ways: (1) by completing the Proxy Form enclosed with the Notice of AGM, (2) via the registrar's website at www.eproxyappointment.com or (3) via the CREST electronic proxy appointment service for those shareholders who are CREST members. In light of the restrictions, shareholders should appoint the Chairman of the meeting as their proxy.

 

Questions

 

Shareholders may submit questions relating to the business of the meeting in advance (so as to be received by no later than 5 p.m. on Friday, 22 May 2020) by email to the Company Secretary, Aisling McCarthy, at amccarthy@uniphar.ie or by post to the Company's registered office, marked for the attention of the Company Secretary.

 

Conference Call

 

For the convenience and safety of shareholders, the AGM will be conducted over a live conference call and shareholders may register to receive participant log-in details at www.directeventreg.com using the conference ID 7495818. The conference call facility is a listening facility only and shareholders will not be able to vote or ask questions via the conference call facility.

 

Updates

 

The Board encourages shareholders to check Regulatory Information Services and the Company's website www.uniphar.ie for any updates in relation to the AGM.

 

 

--- ENDS ---

 

 

 

For further details contact:

 

Uniphar

+353 (0) 1 428 7777

 

 

Brian O'Shaughnessy

 

Group Director of Corporate Development

investor.relations@Uniphar.ie

 

 

Davy

+353 (0) 1 679 6363

(Joint Broker, Nominated Adviser and Euronext

Growth Adviser)

 

 

 

Fergal Meegan

 

Barry Murphy

 

Tom Tynan

 

 

 

RBC Capital Markets (Joint Broker)

+44 (0) 20 7653 4000

 

 

Darrell Uden

 

Jonathan Hardy

 

Jamil Miah

 

 

 

Q4 PR

+353 (0) 1 475 1444 or

(Public Relations Adviser to Uniphar)

+353 87 235 6461

 

 

Iarla Mongey

 

 

 

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,200, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.

 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

 

Commercial & Clinical 

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux and the Nordics, the Group is growing with clients to provide pan-European solutions. Uniphar have built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

 

Product Access 

In Product Access the Group is growing two distinct service offerings: 1) "On-Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions to more than 160 markets globally.

 

Supply Chain & Retail 

Uniphar is an established market leader in Ireland with c50% supply chain market share supported by a network of 287 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the assets and infrastructure are utilised for the benefit of the growth divisions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NOAUWRURROUVAUR
Date   Source Headline
4th Oct 20227:00 amRNSAcquisition of healthcare agency Inspired Health
19th Sep 20227:00 amRNSAcquisition of McCauley Pharmacy Group
14th Sep 20229:08 amRNSDirector/PDMR Shareholding
30th Aug 20227:00 amRNS2022 Interim Results
26th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results
11th May 20224:16 pmRNSResult of AGM
11th May 20227:00 amRNSAGM Statement
7th Apr 20227:00 amRNSNotice of AGM & Annual Report
3rd Mar 20227:31 amRNSDirector/PDMR Shareholding
3rd Mar 20227:29 amRNSExecutive Restricted Share Plan Dealings
1st Mar 20227:00 amRNS2021 Preliminary Results
21st Feb 20228:00 amRNSHolding(s) in Company
26th Jan 20227:00 amRNSFull Year Trading Update & Notice of Results
23rd Dec 20217:00 amRNSAcquisitions of E4H, Devonshire and Navi Group
17th Dec 20217:00 amRNSDirectorate Change
3rd Dec 20217:00 amRNSHolding(s) in Company
23rd Nov 20213:22 pmRNSHolding(s) in Company
15th Nov 20214:02 pmRNSHolding(s) in Company
14th Oct 202111:31 amRNSHolding(s) in Company
7th Sep 20217:00 amRNSHolding(s) in Company
3rd Sep 20217:00 amRNSDirector/PDMR Shareholding
1st Sep 20217:00 amRNS2021 Interim Results
19th Aug 20215:24 pmRNSHolding(s) in Company
2nd Aug 20217:00 amRNSAcquisition of BESTMSLs Group
27th Jul 20217:00 amRNSHalf Year Trading Update and Notice of Results
20th Jul 20217:00 amRNSAcquisition of CoRRect Medical GmbH
12th May 20213:12 pmRNSResult of AGM
12th May 20217:00 amRNSAGM Statement
10th May 20218:29 amRNSHolding(s) in Company
7th May 20218:00 amRNSDirector/PDMR Shareholding
27th Apr 202112:44 pmRNSHolding(s) in Company
16th Apr 20214:59 pmRNSHolding(s) in Company
8th Apr 20217:00 amRNSNotice of AGM & Annual Report
4th Mar 20217:30 amRNSDirector/PDMR Shareholding
4th Mar 20217:30 amRNSExecutive Restricted Share Plan Dealing
2nd Mar 20217:00 amRNS2020 Preliminary Results
25th Feb 20217:00 amRNSConsent to Migration
15th Feb 20213:00 pmRNSResult of EGM
28th Jan 20213:57 pmRNSHolding(s) in Company
27th Jan 20217:00 amRNSDirectorate Changes
27th Jan 20217:00 amRNSFull Year Trading Update & Notice of Results
20th Jan 20219:00 amRNSCurrency Change on LSE
20th Jan 20217:00 amRNSNotice of EGM
7th Jan 20214:27 pmRNSHolding(s) in Company
22nd Dec 20203:00 pmRNSDirector/PDMR Shareholding
9th Dec 20207:00 amRNSAppointment of Joint Corporate Broker
24th Nov 20207:00 amRNSAcquisition of RRD International
23rd Nov 20207:00 amRNSAcquisition
2nd Nov 20203:30 pmRNSHolding(s) in Company
23rd Sep 20207:00 amRNSAcquisition of Diligent Health Solutions

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.